AFLP was a useful tool for identification to species-level and for the ABT-888 supplier discrimination of inter- and intra-patient isolates. Scedosporium prolificans represents the most prevalent species in the respiratory tract of CF patients and immunocompromised patients in Northern-Spain, followed by Pseudallescheria boydii, P. apiosperma, and P. ellipsoidea. CF patients were exclusively colonised with either P. boydii or S. prolificans. Patients were colonised over years exclusively with isolates affiliated to one species, but some patients were colonised with multiple strains with different AFSP. The sum of those

co-colonising strains in one patient, may appear in vitro and in vivo as a multi-resistant S. prolificans isolate, as strains are morphologically identical and might therefore be regarded as only

one strain. A majority of Scedosporium strains (with exception of S. prolificans) were found susceptible for voriconazole and micafungin. Pseudallescheria/Scedosporium Selleck Z-IETD-FMK species are the second most frequently cultured filamentous fungi from the lungs of patients with cystic fibrosis (CF).1 Until 2005, only two clinically relevant species of Scedosporium were known: Scedosporium apiospermum (teleomorph: Pseudallescheria boydii) and S. prolificans. During the last 5 years, several sibling species have been introduced, 1–5 which has led to the subdivision of P. boydii into the following species: S. apiospermum (teleomorph P. apiosperma), S. aurantiacum, S. boydii (teleomorph: P. boydii), S. dehoogii, P. fusoidea, P. ellipsoidea, P. angusta, and P. minutispora. Pseudallescheria Tenoxicam and Scedosporium infections are difficult to treat because of their therapy-refractory nature.6,7 Several infections by multi-drug resistant strains of Scedosporium species have been reported.8–11 Among these, S. prolificans is the most frequently encountered pathogen.12 Delayed diagnosis of the causative agent and ineffective antifungal therapy may have a negative impact on mortality rates of

patients suffering from systemic Scedosporium infections.13,14 Since the segregation of these sibling species, no comprehensive studies on species-specific antifungal susceptibilities and clinical epidemiology have been published. The aim of this study was to provide antifungal susceptibility patterns of isolates identified according to the taxonomy proposed by Gilgado et al.2–5 Strains were identified using AFLP analysis. Moreover, this study provides qualitative molecular epidemiology data on Northern Spanish patients colonised or infected with Scedosporium strains. In total, 60 clinical isolates from 21 patients isolated at the University Hospital Miguel Servet, located in Zaragoza (Northern-East Spain) were included in this study. The University Hospital has an adherence of more than 500 000 persons.